Needham maintains purchase of Gilat and reiterates price target at $8.50 By Investing.com by Technical Terrence Team 02/27/2024 0 © Gilat Satellite Networks PR On Tuesday, Needham & Company maintained its Buy rating and $8.50 price target on shares ...
Needham says macroeconomic factors limit short-term growth of dental market by Technical Terrence Team 11/19/2023 0 Tom Werner/DigitalVision via Getty Images While the market opportunities for dental products and equipment appear to be enormous, macroeconomic factors ...
Despite a slower Q2, Needham sees medtech market growing 7% in 2023 (NYSE:BSX) by Technical Terrence Team 09/04/2023 0 enot-poloskun Needham sees the medtech sector growing by 7% in 2023 versus 5.7% last year, despite slowed growth in Q2, ...
OS Therapeutics, developer of bone cancer drugs, files for $10 million initial public offering (pending: OSTX) 04/04/2023